Welcome to our dedicated page for U S Physical Therapy SEC filings (Ticker: USPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
U.S. Physical Therapy, Inc. (USPH) files a range of reports with the U.S. Securities and Exchange Commission that document its operations as a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services. These SEC filings provide detail on its physical therapy operations segment, industrial injury prevention services, clinic additions and closures, financial performance, and capital allocation decisions.
On this Stock Titan page, investors can review U.S. Physical Therapy’s current reports on Form 8-K, which have recently covered topics such as acquisitions of multi-clinic physical therapy practices and management services companies, quarterly earnings results, dividend declarations, investor presentations, and research reports. For example, the company has filed 8-Ks describing acquisitions of a three-clinic physical therapy practice and a physical therapy management services company that manages a practice with eight clinic locations, as well as 8-Ks reporting results for specific quarters and announcing quarterly cash dividends.
In addition to 8-Ks, U.S. Physical Therapy files annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide segment information for physical therapy operations and industrial injury prevention services, along with discussions of revenue, operating costs, gross profit, and key operating metrics such as total patient visits and net rate per patient visit. These filings also include information about the company’s credit facilities, interest expense, and tax provisions.
Stock Titan enhances access to these documents by offering real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the contents of lengthy filings. Users can quickly see the main points from U.S. Physical Therapy’s 10-K and 10-Q reports, as well as key disclosures from 8-Ks related to acquisitions, earnings, and dividends. This page also serves as a starting point for reviewing any insider transaction reports on Form 4 that may be filed for USPH, alongside the company’s broader regulatory history.
U.S. Physical Therapy (USPH) reported stronger Q3 2025 results. Net revenue rose to $197.1 million from $168.0 million a year ago, and net income attributable to shareholders increased to $13.1 million from $6.6 million. EPS was $0.48 versus $0.39 last year.
Operating income improved to $25.3 million from $12.8 million, supported by higher clinic volumes and contributions from acquired practices. For the first nine months, net revenue reached $578.3 million (vs. $490.9 million) and EPS was $1.85 (vs. $1.32).
The company ended the quarter with cash of $31.1 million, generated operating cash flow of $50.1 million year-to-date, and reported a revolving facility balance of $26.5 million and term loan of $124.4 million (non‑current). USPH added 18 clinics and closed seven in Q3, bringing owned and/or managed clinics to 779, up from 700 a year ago. Recent acquisitions included a 60% stake in a three‑clinic practice for approximately $7.9 million, plus contingent consideration tied to performance.
U.S. Physical Therapy, Inc. reported results for the three and nine months ended September 30, 2025, and attached a press release as Exhibit 99.1.
The Board declared a quarterly dividend of $0.45 per share, payable on December 12, 2025, to shareholders of record on November 17, 2025.
U.S. Physical Therapy, Inc. (USPH) received a Schedule 13G from Copeland Capital Management, LLC disclosing beneficial ownership of 843,981 shares, representing 5.54% of the common stock as of 09/30/2025.
The filer reports sole voting power over 551,532 shares, shared voting power over 144,267 shares, sole dispositive power over 0 shares, and shared dispositive power over 843,981 shares. The reporting person is classified as an investment adviser (IA). The certification and signature were provided by Sofia A. Rosala, General Counsel and CCO.
Nancy Ham, a director of U S Physical Therapy, reported selling 600 shares of the company's common stock on 09/11/2025 at $81.71 per share. After the sale she beneficially owns 1,994 shares in total. That total includes 941 restricted shares granted under the company's Amended and Restated 2003 Stock Incentive Plan, with 470 shares scheduled to lapse (vest) on November 20, 2025 and 471 shares scheduled to lapse on March 6, 2026, subject to her continuing service as a director on those dates.
US Physical Therapy Inc (USPH) Form 144 notice: The filing reports a proposed sale of 600 shares of Common stock through J.P. Morgan Securities LLC with an aggregate market value of $49,026, planned for approximately 09/11/2025 on the NYSE. The shares were acquired by vesting: 1,653 shares vested on 08/20/2025 from restricted stock grants issued between 05/16/2023 and 05/20/2025, with the acquisition characterized as payment for services rendered. The filing also discloses a prior sale of 400 shares on 06/12/2025 by Nancy Ham, generating $31,204 in gross proceeds. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Eric Joseph Williams, President and COO of U S Physical Therapy, reported a sale of 1,000 shares of the company’s common stock on 09/05/2025 at $85.25 per share. After the sale he beneficially owns 25,331 shares, which include 18,210 restricted shares subject to a multi-year vesting schedule if he remains an employee. The restricted shares vest in tranches between November 20, 2025 and March 6, 2029 as specified in the filing. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
USPH Form 4: Christopher J. Reading, Chairman and CEO of U S Physical Therapy Inc (USPH), reported a single transaction on 09/04/2025 selling 2,000 shares of the issuer's common stock at a price of $83.53 per share. After the sale he beneficially owns 114,088 shares in total. The filing discloses that 34,098 of those shares were granted as restricted stock under the companys Amended and Restated 2003 Stock Incentive Plan, with a detailed vesting schedule listing tranche dates and share counts through March 6, 2029, contingent on continued employment.
US Physical Therapy, Inc. (USPH) reported a proposed sale of 1,000 common shares through Rule 144 to be executed on 09/05/2025 on the NYSE via Morgan Stanley Smith Barney LLC. The shares were acquired on 07/01/2024 under the company's Employee Stock Purchase Plan and were paid as compensation. The notice lists an aggregate market value of $85,250.00 for the shares and shows 15,204,119 shares outstanding for the issuer. The filer certifies they are unaware of undisclosed material adverse information and indicates no reportable securities sales in the past three months.
US Physical Therapy, Inc. (USPH) submitted a Form 144 notifying a proposed sale of 2,000 shares of common stock through UBS Financial Services on the NYSE with an aggregate market value of $165,127.20. The shares were originally acquired as restricted stock grants on 04/01/2020 (3,089 shares acquired) and were paid as compensation on the acquisition date. The filing states there were no securities sold by the reporting person in the past three months. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.
US Physical Therapy Inc. (USPH) Chief Financial Officer Carey P. Hendrickson reported a disposal of 698 shares of common stock on 08/25/2025 at an average price of $86.11 per share, leaving beneficial ownership of 27,808 shares. The filing shows Mr. Hendrickson is an officer (Chief Financial Officer) and the Form 4 was filed by one reporting person.
The reported holdings include 14,510 shares issued as restricted stock under the companys Amended and Restated 2003 Stock Incentive Plan. Those restricted shares vest in scheduled tranches from November 20, 2025 through March 6, 2029, contingent on continued employment, with specific share counts and vesting dates provided in the filing.